Equities

Circassia Group PLC

Circassia Group PLC

Actions
Health CareMedical Equipment and Services
  • Price (GBX)34.95
  • Today's Change0.85 / 2.49%
  • Shares traded72.64k
  • 1 Year change-15.27%
  • Beta1.8747
Data delayed at least 20 minutes, as of Aug 12 2022 16:08 BST.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Circassia Group PLC is a United Kingdom-based medical device company, which is focused on point of care asthma diagnosis and management. The Company operates through two segments: NIOX and COPD. The NIOX segment relates to the portfolio of products used to improve asthma diagnosis and management by measuring fractional exhaled nitric oxide (FeNO). The COPD segment relates to the Tudorza and Duaklir Pressair products marketed in the United States, where they are indicated for the maintenance treatment of patients with COPD. Its NIOX FeNO measurement and monitoring products are used by physicians around the world to help improve asthma diagnosis and management. Its FeNO diagnosis and management products helps healthcare to professionals manage their patient's asthma. Its NIOX VERO is a non-invasive, point-of-care system that provides FeNO measurements with 17,000 devices. The Company provides products and services in around 50 countries.

  • Revenue in GBP (TTM)27.90m
  • Net income in GBP2.30m
  • Incorporated2006
  • Employees128.00
  • Location
    Circassia Group PLCNorthbrook House, Robert Robinson AvenueOXFORD OX4 4GAUnited KingdomGBR
  • Phone+44 186 540 5560
  • Fax+44 186 578 4576
  • Websitehttp://www.circassia.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Eco Animal Health Group Plc101.55m5.57m82.28m207.0014.760.98425.800.81030.08230.08231.501.230.91312.173.60490,584.5011.3110.5515.4013.1449.9348.5312.3814.622.57--0.014547.1946.4617.51109.456.21-30.72-29.40
Futura Medical plc.0.00-4.96m100.34m11.00--10.33-----0.018-0.0180.000.03390.00----0.00-73.87-65.78-93.73-86.83-------6,607.25----0.00-------105.85--123.78--
e-Therapeutics plc477.00k-8.07m108.33m32.00--3.77--221.17-0.0169-0.01690.0010.05440.0217--3.3114,906.25-36.62-37.71-38.29-40.40100.00100.00-1,691.82-1,812.91----0.0239--50.47---119.06--42.31--
Scancell Holdings Plc0.00-8.41m109.04m25.00--4.81-----0.0105-0.01050.000.02780.00----0.00-21.98-48.49-24.78-52.14------------0.2598-------181.09------
Faron Pharmaceuticals Oy0.00-17.86m112.05m37.00--43.69-----0.3523-0.35230.000.04620.00----0.00-196.84-165.50-539.12-391.61-------487,178.90---248.330.5486-------25.16--38.80--
Sareum Holdings Plc0.00-1.81m129.33m6.00--22.77-----0.0273-0.02730.000.08340.00----0.00-48.39-49.67-51.44-54.40-------10,610.04----0.00---100.00---52.18------
Creo Medical Group PLC25.16m-24.60m133.30m290.00--1.69--4.94-0.1487-0.14870.1530.40490.26061.775.3486,762.07-25.48---31.67--46.04---97.75--2.67-69.230.1259--166.85---21.06------
Circassia Group PLC27.90m2.30m146.85m128.0078.181.9721.235.170.00440.00750.0640.17420.29452.662.45217,968.802.43-11.692.80-13.9968.1076.198.24-81.991.58--0.0191--16.743.85108.58---22.16--
Animalcare Group Plc74.02m-77.00k172.77m211.00--2.1720.572.31-0.0013-0.00131.231.310.63152.998.57350,824.70-0.0657---0.0768--53.25---0.104--0.96647.160.1221--5.01---132.91------
Bioventix PLC10.50m6.62m175.82m17.0026.8118.0726.0016.751.261.262.001.870.96152.512.78617,437.1060.6552.3765.6955.5592.8392.3063.0865.2910.60123.630.0070.905.9814.65-6.5414.0165.4327.46
Redx Pharma PLC16.29m-18.62m207.65m71.00--31.72--12.75-0.0679-0.06790.05940.01950.38--46.40229,394.40-43.45-40.30-63.41-66.57-----114.35-85.78---10.980.7683--76.52---134.19--11.17--
Data as of Aug 12 2022. Currency figures normalised to Circassia Group PLC's reporting currency: UK Pound GBX

Institutional shareholders

38.81%Per cent of shares held by top holders
HolderShares% Held
Harwood Capital LLPas of 31 Dec 202177.75m18.53%
Lombard Odier Asset Management (Europe) Ltd.as of 07 Aug 202018.13m4.32%
Danske Bank A/S (Investment Management)as of 12 Aug 202215.13m3.61%
Chelverton Asset Management Ltd.as of 31 Dec 202110.00m2.38%
Hargreaves Lansdown Stockbrokers Ltd.as of 01 Aug 20229.89m2.36%
Merchant Capital Manager Ltd.as of 19 Aug 20208.67m2.07%
KW Investment Management Ltd.as of 01 Aug 20227.73m1.84%
Burgundy Asset Management Ltd.as of 31 Oct 20215.45m1.30%
Schroder Investment Management Ltd.as of 15 Aug 20215.20m1.24%
Amiral Gestion SAas of 31 Dec 20214.89m1.17%
More ▼
Data from 31 Dec 2021 - 12 Aug 2022Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.